AbbVie Inc.
HealthcareNYSE:ABBV · New York Stock Exchange
+$2.42 today
Vol 2.08M · Avg 6.53M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $9.4B |
| Receivables | $12.5B |
| Inventory | $5.0B |
| Other Current | $6.6B |
| Total Current Assets | $33.5B |
| PP&E (Net) | $5.7B |
| Goodwill | $35.6B |
| Intangible Assets | $50.9B |
| Long-term Investments | $268.0M |
| Other Non-current | $10.5B |
| Total Non-current Assets | $102.9B |
| Total Assets | $136.5B |
Analysis
Selected assets total $136.5B for Latest. The largest visible component is Intangible Assets at $50.9B, about 37.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.2B -5.3% | $5.5B -56.9% | $12.8B +39.3% | $9.2B -5.6% | $9.7B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $28.0M -9.7% | $31.0M +1450.0% | $2.0M -92.9% | $28.0M -66.7% | $84.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $12.6B +15.3% | $10.9B -2.1% | $11.2B -0.9% | $11.3B +12.8% | $10.0B | $533.8M | $399.4M | -$1.7B |
| Inventory | $5.0B +18.4% | $4.2B +2.0% | $4.1B +14.5% | $3.6B +14.4% | $3.1B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $6.3B +27.2% | $4.9B -0.1% | $4.9B +12.1% | $4.4B | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $29.1B +13.6% | $25.6B -22.5% | $33.0B +15.9% | $28.5B +1.9% | $27.9B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $6.4B +24.0% | $5.1B +2.9% | $5.0B +1.1% | $4.9B -3.4% | $5.1B | $1.2B | $1.5B | $687.8M |
| Goodwill | $35.6B +2.0% | $35.0B +8.2% | $32.3B +0.4% | $32.2B -0.7% | $32.4B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $52.6B -12.4% | $60.1B +8.0% | $55.6B -17.5% | $67.4B -11.2% | $76.0B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $299.0M +7.2% | $279.0M -8.2% | $304.0M +26.1% | $241.0M -13.0% | $277.0M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $10.0B +8.9% | $9.1B +7.4% | $8.5B +52.8% | $5.6B +14.1% | $4.9B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $104.9B -4.3% | $109.6B +7.7% | $101.7B -7.8% | $110.3B -7.0% | $118.6B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $134.0B -0.9% | $135.2B +0.3% | $134.7B -2.9% | $138.8B -5.3% | $146.5B | $13.3B | $11.9B | $10.6B |
| Account Payables | $3.6B +22.0% | $2.9B -20.1% | $3.7B +25.7% | $2.9B +1.8% | $2.9B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $8.7B +28.6% | $6.8B -5.4% | $7.2B +67.2% | $4.3B -66.1% | $12.7B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $25.6B -5.1% | $27.0B +7.4% | $25.2B +20.2% | $20.9B +17.2% | $17.9B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $43.3B +11.7% | $38.7B +2.4% | $37.8B +28.1% | $29.5B -16.1% | $35.2B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $59.6B -1.2% | $60.3B +15.7% | $52.2B -11.8% | $59.1B -7.9% | $64.2B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $8.0B +4.4% | $7.6B -11.6% | $8.6B -0.7% | $8.7B -3.2% | $9.0B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $25.6B +5.1% | $24.4B -2.1% | $24.9B +6.5% | $23.4B +6.3% | $22.0B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $93.9B +0.9% | $93.0B +7.6% | $86.5B -6.0% | $92.0B -4.1% | $95.9B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $137.2B +4.1% | $131.8B +6.0% | $124.3B +2.3% | $121.5B -7.3% | $131.1B | $14.7B | $3.7B | $9.6B |
| Common Stock | $18.0M +0.0% | $18.0M +0.0% | $18.0M +0.0% | $18.0M +0.0% | $18.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$15.5B -96.1% | -$7.9B -690.0% | -$1.0B -120.9% | $4.8B +53.0% | $3.1B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$1.1B +40.6% | -$1.9B +16.5% | -$2.3B -4.8% | -$2.2B +24.1% | -$2.9B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $42.0M +7.7% | $39.0M +5.4% | $37.0M +12.1% | $33.0M +17.9% | $28.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | -$3.2B -196.0% | $3.4B -67.6% | $10.4B -39.9% | $17.3B +12.0% | $15.4B | $9.1B | $7.7B | $3.3B |
| Total Debt | $69.1B +1.8% | $67.8B +12.8% | $60.1B -6.3% | $64.2B -17.3% | $77.6B | $724.2M | $410.6M | $399.4M |
| Net Debt | $63.8B +2.4% | $62.3B +31.7% | $47.3B -14.0% | $55.0B -18.9% | $67.8B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$578.11B
UnitedHealth Group Incorporated
NYSE:UNH
$370.46B
Merck & Co., Inc.
NYSE:MRK
$296.38B
Novartis AG
NYSE:NVS
$292.82B
AstraZeneca PLC
NYSE:AZN
$278.78B
Novo Nordisk A/S
NYSE:NVO
$196.35B
Amgen Inc.
NASDAQ:AMGN
$191.18B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.63B
Pfizer Inc.
NYSE:PFE
$149.30B
Sanofi
NASDAQ:SNY
$106.49B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ABBV have?
AbbVie Inc. (ABBV) reported $5.23B in cash and equivalents in fiscal 2025.
How much debt does ABBV carry?
AbbVie Inc. (ABBV) reported $69.07B of total debt, with net debt of $63.84B.
Explore More
Continue the stock analysis
Jump to another research area for this company.